✦ LIBER ✦

Pharmacological studies with cetrorelix (SB-75), a potent antagonist of luteinising hormone-releasing hormone

✍ Scribed by Th. Reissmann; Th. Klenner; W. Deger; P. Hilgard; G.P. McGregor; K. Voigt; J. Engel

Book ID: 116167932
Publisher: Elsevier Science
Year: 1996
Tongue: English
Weight: 762 KB
Volume: 32
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(96)00138-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of experimental DMBA induced m

Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone

✍ Thomas Reissmann; Peter Hilgard; Johannes H. Harleman; Jürgen Engel; Ana M. Coma 📂 Article 📅 1992 🏛 Springer-Verlag 🌐 English ⚖ 987 KB

Systematic delivery of the luteinizing h

Systematic delivery of the luteinizing hormone-releasing hormone (LH-RH) antagonist cetrorelix (SB-75) via pulmonary instillation in the unanesthetized awake sheep

✍ Schreier, Hans; Engel, Jürgen; McNicol, Ken J.; Derendorf, Hartmut; Groot, Kate; 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 302 KB

Luteinizing hormone-releasing hormone an

Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice

✍ Jungwirth, Andreas; Galvan, Georg; Pinski, Jacek; Halmos, Gabor; Szepeshazi, Kar 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

## Background: Hormones like bombesin (bn)/gastrin-releasing peptide (grp) and luteinizing hormone-releasing hormone (lh-rh) and growth factors such as epidermal growth factor (egf) might be involved in the relapse of prostate cancer under androgen ablation therapy. interference with receptors for

Phase II study of cetrorelix, a luteiniz

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer

✍ Claire F Verschraegen; Silke Westphalen; Wei Hu; Evelyne Loyer; Andrzej Kudelka; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 130 KB

Inhibition of growth of androgen-indepen

Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II

✍ A. Jungwirth; J. Pinski; G. Galvan; G. Halmos; K. Szepeshazi; R.Z. Gai; K. Groot 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 966 KB

Changes in subcellular distribution of p

Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix

✍ Halmos, G.; Schally, A. V. 📂 Article 📅 2002 🏛 National Academy of Sciences 🌐 English ⚖ 120 KB